Nested case–control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage

Abstract

We carried out a nested case-control study to measure the rate ratio (RR) for invasive female breast cancer in relation to non-steroidal anti-inflammatory drug (NSAID) use. The source population consisted of the female beneficiaries of the Saskatchewan Prescription Drug Plan from 1981 to 1995 with no history of cancer since 1970. Four controls/case, matched on age and sampling time, were randomly selected. Dispensing rates during successive time periods characterized NSAID exposure. RRs associated with exposure during each period were adjusted for exposure during the others. Confounding by other determinants was studied in analyses adjusted with data obtained by interviewing samples of subjects accrued from mid-1991 to mid-1995. We accrued 5882 cases and 23,517 controls. Increasing NSAID exposure 2-5 years preceding diagnosis was associated with a trend towards a decreasing RR (P-trend = 0.003); for the highest exposure level RR = 0.76, 95% confidence interval 0.63-0.92. This protective effect could not be attributed to confounding by other determinants. In analyses involving only the cases, NSAID exposure 2-5 and 6-10 years preceding diagnosis was associated with significantly reduced risks of presenting with a large tumour (> 5 cm diameter) or distant metastasis, but not regional lymph node metastasis. The use of NSAIDs may retard the growth of breast cancers and prevent distant metastasis.

References 32

1. 1.

   Cain K. C., Breslow N. E. Logistic regression analysis and efficient design for two-stage studies. Am J Epidemiol. 1988;128(6):1198-1206.

   Not in our library10.1093/oxfordjournals.aje.a115074

2. 2.

   Collet J. P., Sharpe C., Belzile E., Boivin J. F., Hanley J., Abenhaim L. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer. 1999;81(1):62-68.

   Not in our library10.1038/sj.bjc.6690651

3. 3.

   Connolly J. M., Liu X. H., Rose D. P. Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor. Nutr Cancer. 1996;25(3):231-240.

   Not in our library10.1080/01635589609514447

4. 4.

   Connolly J. M., Rose D. P. Effects of fatty acids on invasion through reconstituted basement membrane ('Matrigel') by a human breast cancer cell line. Cancer Lett. 1993;75(2):137-142.

   Not in our library10.1016/0304-3835(93)90198-i

5. 5.

   Day N. E., Byar D. P., Green S. B. Overadjustment in case-control studies. Am J Epidemiol. 1980;112(5):696-706.

   Not in our library10.1093/oxfordjournals.aje.a113042

6. 6.

   Egan K. M., Stampfer M. J., Giovannucci E., Rosner B. A., Colditz G. A. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 1996;88(14):988-993.

   Not in our library10.1093/jnci/88.14.988

7. 7.

   Folkman J. The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Res Treat. 1995;36(2):109-118.

   Not in our library10.1007/bf00666033

8. 8.

   Friedman G. D., Ury H. K. Initial screening for carcinogenicity of commonly used drugs. J Natl Cancer Inst. 1980;65(4):723-733.

   Not in our library10.1093/jnci/65.4.723

9. 9.

   Gammon M. D., John E. M., Britton J. A. Recreational and occupational physical activities and risk of breast cancer. J Natl Cancer Inst. 1998;90(2):100-117.

   Not in our library10.1093/jnci/90.2.100

10. 10.

    Gridley G., McLaughlin J. K., Ekbom A., Klareskog L., Adami H. O., Hacker D. G., Hoover R., Fraumeni J. F. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst. 1993;85(4):307-311.

    Not in our library10.1093/jnci/85.4.307

11. 11.

    Han E. K., Arber N., Yamamoto H., Lim J. T., Delohery T., Pamukcu R., Piazza G. A., Xing W. Q., Weinstein I. B. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat. 1998;48(3):195-203.

    Not in our library10.1023/a:1005924730450

12. 12.

    Harris R. E., Namboodiri K. K., Farrar W. B. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996;7(2):203-205.

    Not in our library10.1097/00001648-199603000-00017

13. 13.

    Harris R. E., Namboodiri K., Stellman S. D., Wynder E. L. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med. 1995;24(2):119-120.

    Not in our library10.1006/pmed.1995.1022

14. 14.

    Hubbard N. E., Chapkin R. S., Erickson K. L. Inhibition of growth and linoleate-enhanced metastasis of a transplantable mouse mammary tumor by indomethacin. Cancer Lett. 1988;43(1-2):111-120.

    Not in our library10.1016/0304-3835(88)90222-4

15. 15.

    Hudson N., Balsitis M., Everitt S., Hawkey C. J. Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs. Gut. 1995;37(2):191-194.

    Not in our library10.1136/gut.37.2.191

16. 16.

    Hunter C. P., Redmond C. K., Chen V. W., Austin D. F., Greenberg R. S., Correa P., Muss H. B., Forman M. R., Wesley M. N., Blacklow R. S. Breast cancer: factors associated with stage at diagnosis in black and white women. Black/White Cancer Survival Study Group. J Natl Cancer Inst. 1993;85(14):1129-1137.

    Not in our library10.1093/jnci/85.14.1129

17. 17.

    Hwang D., Scollard D., Byrne J., Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90(6):455-460.

    Not in our library10.1093/jnci/90.6.455

18. 18.

    Isomäki H. A., Hakulinen T., Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis. 1978;31(11):691-696.

    Not in our library10.1016/0021-9681(78)90071-1

19. 19.

    Khoo N. K., Chan F. P., Saarloos M. N., Lala P. K. Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2. Clin Exp Metastasis. 1992;10(4):239-252.

    Not in our library10.1007/bf00133559

20. 20.

    Lala P. K., Al-Mutter N., Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer. 1997;73(3):371-380.

    Not in our library10.1002/(sici)1097-0215(19971104)73:3<371::aid-ijc12>3.0.co;2-g

21. 21.

    Mickey R. M., Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129(1):125-137.

    Not in our library10.1093/oxfordjournals.aje.a115101

22. 22.
    Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and year · 1992

    No notice
23. 23.

    Risch H. A., Howe G. R. Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study. Am J Epidemiol. 1994;139(7):670-683.

    Not in our library10.1093/oxfordjournals.aje.a117057

24. 24.

    Robertson F. M., Parrett M. L., Joarder F. S., Ross M., Abou-Issa H. M., Alshafie G., Harris R. E. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett. 1998;122(1-2):165-175.

    Not in our library10.1016/s0304-3835(97)00387-x

25. 25.

    Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5(2):138-146.

    Not in our library10.1097/00001648-199403000-00003

26. 26.

    Taketo M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst. 1998;90(20):1529-1536.

    Not in our library10.1093/jnci/90.20.1529

27. 27.

    Thompson H. J., Briggs S., Paranka N. S., Piazza G. A., Brendel K., Gross P. H., Sperl G. J., Pamukcu R., Ahnen D. J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst. 1995;87(16):1259-1260.

    Not in our library

28. 28.

    Thun M. J., Namboodiri M. M., Calle E. E., Flanders W. D., Heath C. W. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53(6):1322-1327.

    Not in our library

29. 29.

    Thune I., Brenn T., Lund E., Gaard M. Physical activity and the risk of breast cancer. N Engl J Med. 1997;336(18):1269-1275.

    Not in our library10.1056/nejm199705013361801

30. 30.

    Vainio H., Morgan G. Cyclo-oxygenase 2 and breast cancer prevention. Non-steroidal anti-inflammatory agents are worth testing in breast cancer. BMJ. 1998;317(7162):828-828.

    Not in our library10.1136/bmj.317.7162.828

31. 31.

    Walter S. D., Day N. E. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol. 1983;118(6):865-886.

    Not in our library10.1093/oxfordjournals.aje.a113705

32. 32.

    Ziche M., Jones J., Gullino P. M. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst. 1982;69(2):475-482.

    Not in our library

Cited by papers we hold 2

• Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner · 2020
  Not checked
• Breast cancer and NSAID use: a meta-analysis · 2001
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.